Repository logo
 

Development of Antibody-Directed Therapies: Quo Vadis?

Accepted version
Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/273730

Repository DOI

https://doi.org/10.17863/CAM.20789
Thumbnail Image

Files

Accepted version (3.55 MB)

Type

Article

Change log

Authors

Bernardes, Gonçalo JL  ORCID logo  https://orcid.org/0000-0001-6594-8917

Abstract

Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.

Description

Keywords

anti-tumor agents, antibody-drug conjugates, bioconjugation, drug delivery, linkers, Animals, Breast Neoplasms, Bystander Effect, Cell Line, Tumor, Drug Liberation, Female, Humans, Immunoconjugates, Mice, Neoplasms, Oligopeptides, Transplantation, Heterologous

Journal Title

Angew Chem Int Ed Engl

Conference Name

Journal ISSN

1433-7851
1521-3773

Volume Title

57

Publisher

Wiley

Publisher DOI

https://doi.org/10.1002/anie.201712185

Rights and licensing

All rights reserved
Except where otherwised noted, this item's license is described as All rights reserved
Sponsorship
Engineering and Physical Sciences Research Council (EP/M003647/1)
The Royal Society (uf110046)
European Research Council (676832)
European Commission (EC) (852985)

Collections

Scholarly Works - Chemistry